Axios Pro · Jun 2025
Reports the Series A and frames the company’s fruit-fly platform as a more sustainable alternative to traditional recombinant protein manufacturing.
We make unmakeable proteins with radical advanced biomanufacturing.
Company research
Public company, workplace, funding, and market signals
Overview
Edmonton-based biotechnology company founded in 2018 that uses its fruit-fly-based EntoEngine® platform to produce difficult-to-express recombinant proteins for life sciences, agriculture, and food innovation customers. Public sources describe it as an active, privately held biotech business with an onsite Edmonton workspace, roughly 38 employees, and about $26.9M raised to date.
Primary product
Custom recombinant protein expression and contract protein production via the EntoEngine® platform
Founded
2018
Headquarters
Edmonton, Alberta, Canada
Team size
11-50
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
Synthetic biology biomanufacturing / recombinant protein expression